Analyst Group’s Updated Analysis of Chordate Medical: International Attention

Analyst Group has published an updated analysis of Chordate Medical following the company’s Q2 report released on August 31, 2023. In the analysis, Analyst Group comments on Chordate’s sales efforts with a focus on a future exit strategy and the international attention garnered by the company’s migraine study:

“Chordate’s migraine study, PM007, was presented in June at the American Headache Society Scientific Meeting in Austin, Texas, as well as at the German Migraine and Headache Society congress in Berlin. The presentations were well-received and generated significant interest, with Chordate confirming the substantial need for an additional treatment option for chronic migraines through discussions with medical professionals. Subsequently, Chordate has been invited to present its migraine treatment at the International Headache Congress (IHC) 2023 in Seoul in September, and in October, Chordate will also be present at the Deutscher Schmerzkongress in Mannheim. In November, the company will participate in Neurologdagarna in Helsinki. It is abundantly clear that Chordate has rapidly gained and continues to receive a great deal of attention regarding its migraine treatment.”

Read the full analysis (in Swedish)

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy